Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218407 · ClinicalTrials.gov registry record · Phase 1
Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain
A Phase 1 study of Chronic Pain and Low Back Pain, sponsored by Evon Medics.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT06218407 is a Phase 1 study of Chronic Pain and Low Back Pain that has completed, run by Evon Medics. The registered enrollment target is 86 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06218407, a Phase 1 study of Chronic Pain and Low Back Pain, has completed, sponsored by Evon Medics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this study phase, Phase I component is to configure Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) into Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain CBOT-Pain (or CBOT-P) for rapid and sustained reduction of Pain, Negative Affect (NA) and Cognitive Impairments. The investigators aimed at first establishing if stimulation parameters targeting key olfactory regions, and their associated networks, paired with tasks that synergistically activate the orbitofrontal cortex (OFC) would have significantly different acute (\< 7 days) effects in pain and NA intensity reductions. The hypothesis is that the short burst paradigm will more effectively activate the medial OFC and its functional connectivity with medial temporal affective networks, and result in greater reduction of affect and pain severity ratings after 7 days. The investigators will further examine if enhancing the odor regimen with beta-caryophyllene (BCP) content would have more dramatic effects in acute relief of pain, NA, and cognition. Aim 1.1: To optimize CBOT-P stimulation parameters and olfactory stimulants for pain, affect and cognition in CP with and without high NA. This is a 14-day prospective study, in which fMRI and rs-fMRI will be acquired at baseline and day 7 during exposure to short vs long-burst CBOT stimulations. This is followed by daily treatment with short-burst versus long-burst CBOT paradigm over 14 days, during which pain and NA measures will be recorded daily by the subjects, and assessed by train research staff at baseline, day 7 and day 14. Aim 1.2: To determine if CBOT regimen optimized with BCP content produces stronger and faster pain and affective response. This is a 14-day prospective study design, in which daily treatment of CBOT-PLUS (i.e., CBOT with BCP) will be compared against daily treatment with CBOT without BCP enhancement (CBOT). Subjects and clinicians are blinded to the assigned a
Conditions Studied
Interventions
- COMBINATION_PRODUCT Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)
- COMBINATION_PRODUCT Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm
- COMBINATION_PRODUCT Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm
- COMBINATION_PRODUCT Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)
Study Locations (1)
District of Columbia
- Howard University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-04-27 |
| Est. Completion | 2023-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06218407
The ClinicalTrials.gov registry entry for NCT06218407 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (89% lower). The listed sponsor is Evon Medics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 4 interventions - of which Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) is the first listed.
NCT06218407 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06218407 about?
NCT06218407 is a clinical study titled "Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain". The overarching goal of this study phase, Phase I component is to configure Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) into Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain CBOT-Pain (or CBOT-P) for rapid and sustained reduction of Pai...
What is the current status of trial NCT06218407?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2023-04-27. Estimated completion is 2023-09-15.
What conditions does trial NCT06218407 study?
This clinical trial studies the following conditions: Chronic Pain, Low Back Pain.
What interventions are being tested in trial NCT06218407?
The interventions under investigation include: Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) (COMBINATION_PRODUCT), Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm (COMBINATION_PRODUCT), Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm (COMBINATION_PRODUCT), Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06218407?
This trial is sponsored by Evon Medics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218407 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Managing Chronic Tendon Pain by Metformin
RECRUITING · Phase 1
-
Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling
RECRUITING · Phase 1
-
ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain
RECRUITING · Phase 1
-
Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis
RECRUITING · Phase 1
-
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
RECRUITING · Phase 1
-
Cognitive Behavioral Therapy for Insomnia in Chronic Pain Patients
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.